This company has been marked as potentially delisted and may not be actively trading. Tocagen (TOCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TOCA vs. ABUS, KALV, ANAB, ARVN, ORGO, TRVI, PHAR, CRMD, KROS, and AKBAShould you be buying Tocagen stock or one of its competitors? The main competitors of Tocagen include Arbutus Biopharma (ABUS), KalVista Pharmaceuticals (KALV), AnaptysBio (ANAB), Arvinas (ARVN), Organogenesis (ORGO), Trevi Therapeutics (TRVI), Pharming Group (PHAR), CorMedix (CRMD), Keros Therapeutics (KROS), and Akebia Therapeutics (AKBA). These companies are all part of the "medical" sector. Tocagen vs. Arbutus Biopharma KalVista Pharmaceuticals AnaptysBio Arvinas Organogenesis Trevi Therapeutics Pharming Group CorMedix Keros Therapeutics Akebia Therapeutics Tocagen (NASDAQ:TOCA) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment. Do analysts rate TOCA or ABUS? Arbutus Biopharma has a consensus price target of $5.50, indicating a potential upside of 54.93%. Given Arbutus Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Arbutus Biopharma is more favorable than Tocagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tocagen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, TOCA or ABUS? Tocagen has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Does the MarketBeat Community prefer TOCA or ABUS? Arbutus Biopharma received 193 more outperform votes than Tocagen when rated by MarketBeat users. Likewise, 70.66% of users gave Arbutus Biopharma an outperform vote while only 66.03% of users gave Tocagen an outperform vote. CompanyUnderperformOutperformTocagenOutperform Votes24366.03% Underperform Votes12533.97% Arbutus BiopharmaOutperform Votes43670.66% Underperform Votes18129.34% Does the media favor TOCA or ABUS? In the previous week, Arbutus Biopharma had 7 more articles in the media than Tocagen. MarketBeat recorded 7 mentions for Arbutus Biopharma and 0 mentions for Tocagen. Arbutus Biopharma's average media sentiment score of 0.74 beat Tocagen's score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Tocagen Neutral Arbutus Biopharma Positive Do insiders & institutionals have more ownership in TOCA or ABUS? 21.4% of Tocagen shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 10.9% of Tocagen shares are owned by insiders. Comparatively, 20.3% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Is TOCA or ABUS more profitable? Arbutus Biopharma has a net margin of -1,137.65% compared to Tocagen's net margin of -176,433.34%. Arbutus Biopharma's return on equity of -68.18% beat Tocagen's return on equity.Company Net Margins Return on Equity Return on Assets Tocagen-176,433.34% -327.74% -111.87% Arbutus Biopharma -1,137.65%-68.18%-51.55% Which has higher earnings and valuation, TOCA or ABUS? Tocagen has higher earnings, but lower revenue than Arbutus Biopharma. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTocagen$40K4,390.93-$63.52M-$2.69-2.73Arbutus Biopharma$6.17M110.15-$72.85M-$0.38-9.34 SummaryArbutus Biopharma beats Tocagen on 15 of the 18 factors compared between the two stocks. Get Tocagen News Delivered to You Automatically Sign up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TOCA vs. The Competition Export to ExcelMetricTocagenPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$175.64M$6.90B$5.57B$7.83BDividend YieldN/A3.06%5.11%4.22%P/E Ratio-3.107.4422.4218.48Price / Sales4,390.93242.73394.10103.91Price / CashN/A65.8538.1834.62Price / Book16.326.516.774.25Net Income-$63.52M$143.21M$3.22B$248.23M Tocagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TOCATocagenN/A$7.30-0.6%N/A+890.6%$174.61M$40,000.00-3.0877Gap DownABUSArbutus Biopharma1.9901 of 5 stars$3.41+2.1%$5.50+61.3%+30.0%$652.95M$6.17M-7.9390KALVKalVista Pharmaceuticals4.3533 of 5 stars$13.08+0.6%$24.83+89.9%+21.3%$650.29MN/A-3.59100Positive NewsANABAnaptysBio2.4505 of 5 stars$21.18-0.7%$33.63+58.8%-8.7%$649.53M$91.28M-3.48100Upcoming EarningsNews CoveragePositive NewsARVNArvinas3.0543 of 5 stars$9.37+1.7%$34.33+266.4%-69.7%$644.39M$263.40M-3.38420Short Interest ↑News CoverageORGOOrganogenesis3.4345 of 5 stars$4.88+4.5%$5.50+12.7%+108.9%$618.92M$482.04M-81.33950Upcoming EarningsNews CoveragePositive NewsTRVITrevi Therapeutics3.6034 of 5 stars$6.31-4.2%$17.56+178.3%+135.8%$610.06MN/A-14.3420Upcoming EarningsNews CoveragePositive NewsHigh Trading VolumePHARPharming Group2.724 of 5 stars$8.79+3.2%$30.00+241.5%-6.6%$597.65M$297.20M-33.79280Upcoming EarningsShort Interest ↓News CoveragePositive NewsGap UpCRMDCorMedix2.4834 of 5 stars$9.12+0.7%$14.50+59.0%+74.9%$594.46M$43.47M-11.2630Upcoming EarningsPositive NewsKROSKeros Therapeutics3.0986 of 5 stars$14.45+1.3%$40.33+179.1%-74.4%$586.83M$3.55M-2.77100Upcoming EarningsPositive NewsAKBAAkebia Therapeutics4.0739 of 5 stars$2.43flat$6.63+172.6%+91.3%$574.04M$160.18M-10.56430Upcoming EarningsAnalyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies Arbutus Biopharma Alternatives KalVista Pharmaceuticals Alternatives AnaptysBio Alternatives Arvinas Alternatives Organogenesis Alternatives Trevi Therapeutics Alternatives Pharming Group Alternatives CorMedix Alternatives Keros Therapeutics Alternatives Akebia Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TOCA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tocagen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tocagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TOCA Stock Free TOCA Stock Alerts